HealthMet and Workplace Surveillance Custom Case Solution & Analysis

Evidence Brief

Financial Metrics

• Revenue Concentration: The client Dax represents 22 percent of the total annual recurring revenue for HealthMet.
• Funding Status: HealthMet recently secured 15 million dollars in Series B funding to expand its predictive analytics capabilities.
• Customer Acquisition: The cost to acquire a corporate client of the scale of Dax is estimated at 18 months of sales effort and 250,000 dollars in direct marketing expenses.
• Market Valuation: Current valuation is tied to the growth of the user base and the accuracy of the predictive health algorithms.

Operational Facts

• Data Collection: The platform tracks heart rate variability, sleep cycles, and physical activity via wearable integration.
• Privacy Architecture: The current user agreement states that individual data is anonymized and only aggregate trends are visible to the employer.
• Algorithm Alert: The system flagged a specific pattern in a small team at Dax that correlates with high-risk health events, potentially identifying a specific individual through process of elimination.
• Headcount: HealthMet employs 45 people, with 60 percent dedicated to data science and engineering.

Stakeholder Positions

• Sarah Jenkins (CEO): Committed to the original mission of improving health but feels the pressure of the Dax contract renewal.
• Dax HR Director: Views the data as a tool for risk management and cost containment. Argues that since Dax pays for the service, they own the insights.
• HealthMet Engineering Team: Strongly opposed to de-anonymizing data, citing ethical breaches and potential user revolt.
• End Users (Employees): Participation is voluntary but incentivized. Their trust is based on the promise of privacy.

Information Gaps

• Legal Liability: The case does not specify the exact liquidated damages clause in the Dax contract if data access is denied.
• User Churn: There is no data on how many users would stop using the device if they knew the employer had granular access.
• Regulatory Environment: Specific jurisdictional privacy laws governing workplace health data are not detailed.

Strategic Analysis

Core Strategic Question

The central dilemma is whether HealthMet can maintain a viable B2B business model if it refuses to provide the specific risk-mitigation data that its largest buyers demand. The strategic conflict pits short-term financial stability against the long-term integrity of the data source.

Structural Analysis

• Buyer Power: High. Dax represents nearly a quarter of revenue, giving them significant leverage over product roadmaps and policy.
• Threat of Substitutes: Moderate. Competitors are willing to offer more aggressive surveillance features, threatening HealthMet with commoditization if they remain purely a wellness play.
• Regulatory Pressure: Increasing. Emerging data privacy laws make the possession and sharing of identifiable health data a massive balance sheet liability.

Strategic Options

Option 1: Strict Privacy Adherence. Reject the request from Dax and maintain the current anonymization wall.
Rationale: Protects the brand and ensures high user participation.
Trade-offs: Risk of losing 22 percent of revenue and damaging the reputation among other corporate buyers.
Resource Requirements: Requires a pivot in sales strategy to diversify the client base and reduce dependency on Dax.

Option 2: Mediated Consent Model. Implement a feature where the system asks the flagged individual for permission to share their status with HR in exchange for support.
Rationale: Maintains ethical standards while providing the employer a path to intervention.
Trade-offs: Users may feel coerced; Dax may find the process too slow for risk management.
Resource Requirements: Significant engineering hours to build the consent workflow and legal review of the new terms.

Option 3: Data Aggregation Minimums. Increase the minimum cohort size for reporting to prevent individual identification.
Rationale: Hardens the privacy wall through technical constraints.
Trade-offs: Reduces the utility of the product for small teams or departments.
Resource Requirements: Minimal technical changes but requires a difficult negotiation with the Dax HR team.

Preliminary Recommendation

HealthMet must choose Option 1. The long-term value of the company is entirely dependent on the quality of the data collected. If employees perceive the wearable as a corporate tracking device, they will either stop wearing it or manipulate the data. This destroys the product's efficacy and the firm's valuation. Losing Dax is a financial setback; losing user trust is a terminal event.

Implementation Roadmap

Critical Path

• Phase 1 (Days 1-15): Conduct a formal legal audit of the Dax contract to identify any wiggle room regarding data definitions. Prepare a formal refusal brief based on data integrity and liability.
• Phase 2 (Days 16-45): Launch a user-facing transparency campaign. Update the privacy interface to show users exactly what the employer can and cannot see. This builds a defensive wall of user expectation.
• Phase 3 (Days 46-90): Renegotiate the Dax contract. Offer enhanced aggregate reporting and new wellness workshops in lieu of individual data access. Simultaneously, the sales team must initiate three new enterprise pilots to dilute Dax's revenue share.

Key Constraints

• Revenue Gap: The 22 percent revenue hole cannot be filled in 90 days. The board must be prepared for a temporary dip in growth metrics.
• Client Relationship: The Dax HR Director has made this a personal priority. The CEO must manage this relationship directly to prevent an immediate contract termination.

Risk-Adjusted Implementation Strategy

The primary risk is a sudden exit by Dax. To mitigate this, the implementation includes a contingency plan to reduce non-essential spending if the contract is terminated. The strategy focuses on hardening the technical privacy layer so that the CEO can truthfully tell Dax that the system is no longer capable of providing individual-level health alerts. This shifts the conversation from a refusal to a technical limitation.

Executive Review and BLUF

BLUF

Deny the Dax request for individual-level data. HealthMet's valuation and survival depend on user trust and data accuracy. If employees believe the platform facilitates workplace discrimination or surveillance, they will cease using the product or provide low-quality data. This outcome would render the HealthMet algorithm useless. The company should accept the risk of losing the Dax contract to preserve its structural integrity. 22 percent revenue loss is preferable to a total collapse of the business model. The CEO must frame this refusal as a move to protect the client from the massive legal and regulatory liabilities associated with possessing identifiable employee health records.

Dangerous Assumption

The analysis assumes that Dax will actually cancel the contract if denied. In reality, Dax has already invested significant time and resources into the HealthMet platform. The switching costs for Dax are high, and they may be posturing to see how much data they can extract without a genuine intent to exit.

Unaddressed Risks

• Competitor Aggression: A more permissive competitor may approach Dax immediately following a refusal, offering the exact surveillance features HealthMet denies. Probability: High. Consequence: Loss of market share in the high-surveillance segment.
• Employee Whistleblowing: If word leaks that Dax even requested this data, it could trigger a PR crisis for both companies. Probability: Moderate. Consequence: Severe brand damage and potential regulatory investigation.

Unconsidered Alternative

HealthMet could pivot to a direct-to-employee subscription model where the employer pays for the benefit but has zero visibility into the data, even in aggregate. This would remove the conflict of interest entirely by repositioning the employer as a benefactor rather than a data consumer. This moves the product from a surveillance tool to a pure employee benefit, which may command a different but more stable market premium.

Verdict: APPROVED FOR LEADERSHIP REVIEW